Recombinant Human PARG Protein, His-tagged
Cat.No. : | PARG-1530H |
Product Overview : | Recombinant human PARG protein (Met1~Thr976) with a N-terminal His tag was expressed in E.coli. |
Unit | |
Price | |
Qty |
- Specification
- Gene Information
- Related Products
Description : | Poly(ADP-ribose) glycohydrolase (PARG) is the major enzyme responsible for the catabolism of poly(ADP-ribose), a reversible covalent-modifier of chromosomal proteins. The protein is found in many tissues and may be subject to proteolysis generating smaller, active products. Several transcript variants encoding different isoforms have been found for this gene. |
Source : | E.coli |
Species : | Human |
Tag : | His |
Form : | Freeze-dried powder |
Molecular Mass : | 115 kDa |
Endotoxin : | <1.0EU per 1µg (determined by the LAL method) |
Purity : | > 97% |
Applications : | Positive Control; Immunogen; SDS-PAGE; WB. |
Stability : | The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37 centigrade for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition. |
Storage : | Avoid repeated freeze/thaw cycles. Store at 2-8 centigrade for one month. Aliquot and store at -80 centigrade for 12 months. |
Concentration : | 200 µg/mL |
Storage Buffer : | 20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300. |
Reconstitution : | Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex. |
Gene Name : | PARG poly(ADP-ribose) glycohydrolase [ Homo sapiens (human) ] |
Official Symbol : | PARG |
Synonyms : | PARG; poly(ADP-ribose) glycohydrolase; PARG99; poly(ADP-ribose) glycohydrolase; mitochondrial poly(ADP-ribose) glycohydrolase; poly(ADP-ribose) glycohydrolase 60 kDa isoform; EC 3.2.1.143 |
Gene ID : | 8505 |
mRNA Refseq : | NM_003631 |
Protein Refseq : | NP_003622 |
MIM : | 603501 |
UniProt ID : | Q86W56 |
Products Types
◆ Recombinant Protein | ||
PARG-3934R | Recombinant Rat PARG Protein, His (Fc)-Avi-tagged | +Inquiry |
PARG-1171H | Recombinant Human PARG Protein, His-tagged | +Inquiry |
PARG-2548H | Recombinant Human PARG Protein, His-tagged | +Inquiry |
PARG-31H | Active Recombinant Human PARG protein, His-tagged | +Inquiry |
PARG-87H | Recombinant Human PARG Protein, GST-tagged | +Inquiry |
◆ Lysates | ||
PARG-3434HCL | Recombinant Human PARG 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (6)
Ask a questionStudies have shown that the aberrant expression of PARG is related to the occurrence and development of a variety of tumors, such as lung cancer, breast cancer, colon cancer, etc. High expression of PARG may promote the proliferation and metastasis of tumor cells, which is associated with poor prognosis.
There are interactions between PARG and other biomolecules. For example, it interacts with DNA repair enzymes to participate in the DNA repair process, and also interacts with apoptosis-related proteins to regulate the apoptosis process.
Biomolecules that can be used as molecular markers for PAR include its mRNA and protein expression products in tissues and cells, as well as other biomolecules that interact with it (e.g., DNA repair enzymes, apoptosis-related proteins, etc.). These markers can be used for early diagnosis of diseases, prognosis judgment, or monitoring the effectiveness of treatment.
Therapeutic strategies for PAGR include inhibition of its activity, regulation of its expression, and gene therapy. For example, the development of small molecule inhibitors or antibody drugs against PAGR to inhibit its overactivation in tumors, or the regulation of PAGR expression through gene knockout or overexpression techniques.
PARG is mainly involved in DNA repair and apoptosis processes within the cell. When DNA is damaged, PARG promotes the initiation of DNA repair mechanisms to restore the normal function of the cell. If the DNA damage cannot be repaired, PARG is involved in the process of apoptosis, removing the damaged cells.
Evaluating the efficacy and safety of treatments for PARG requires clinical trials and drug monitoring. The effectiveness of the treatment was evaluated by designing a rigorous clinical trial protocol that compared the disease response rate, survival, and quality of life between the treatment and control groups. At the same time, drug monitoring is used to monitor the safety and efficacy of drugs in actual use, adjust treatment regimens in a timely manner, maximize the efficacy of drugs and reduce the risk of side effects.
Customer Reviews (3)
Write a reviewIt is well active and can remain active for a long time.
The preparation process of PAREG is strictly controlled to ensure the quality and safety of the product.
Very convenient to use and highly recommended.
Ask a Question for All PARG Products
Required fields are marked with *
My Review for All PARG Products
Required fields are marked with *
Inquiry Basket